Novel therapies against aggressive differentiated thyroid carcinomas

International Journal of Endocrine Oncology

Valeriano Leite¹  Rita Santos¹  Sara Donato¹  Helder Simões¹ 

[1] 1Endocrinology Department, Instituto Português de Oncologia de Lisboa, Francisco Gentil, Lisbon, Portugal;

关键词: antineoplastic agents;    molecular-targeted therapy;    protein kinase inhibitors;    thyroid neoplasms/therapy;   

DOI  :  10.2217/ije-2017-0022

来源: DOAJ

【 摘 要 】

The incidence of thyroid cancer (TC) is increasing. Although the majority of these cancers have a good prognosis, 10% of these will develop local recurrence and/or distant metastases. Conventional cytotoxic chemotherapy has been largely replaced by molecular-target therapies, but it can still have a role. Two tyrosine kinase inhibitors have been approved for the treatment of advanced differentiated TC. They significantly improve progression-free survival, but at the cost of frequent and potentially serious adverse effects. At the moment, there are multiple clinical trials with other tyrosine kinase inhibitors and other drugs. We present a review of the current standard of care and what is up to come in the treatment of advanced TC.

【 授权许可】

Unknown